TiumBio grants Chiesi rights to develop TGF-β molecules to treat respiratory diseases

TiumBio Co. Ltd. (Seongnam, South Korea) granted Chiesi Farmaceutici S.p.A. (Parma, Italy) exclusive, worldwide rights to develop and commercialize small molecules targeting transforming growth factor beta (TGF-β) signaling.

The partners said the deal covers respiratory diseases including idiopathic pulmonary fibrosis (IPF). TiumBio retains development and commercialization rights for all other indications...